Literature DB >> 3478328

In-vitro activity of two new carbapenems FCE 22101 and CGP 31608 in comparison with imipenem.

P Van der Auwera1, F Ernst, P Grenier, Y Glupczynski, M Husson, J Klastersky.   

Abstract

The minimum inhibitory concentrations (MICs) of two new penems, CGP 31608 and FCE 22101 were evaluated against 993 aerobic Gram-positive and Gram-negative bacteria and compared with imipenem. FCE 22101 was usually two to eight-fold more active than CGP 31608 except for Pseudomonas aeruginosa against which FCE 22101 was inactive. Both new penems were less active than imipenem. MBCs were equal to 1-2 X MICs. The effects of inocula, cations and serum were minimal. The MICs and MBCs were higher at pH 8 than at pH 6 or 7. Synergy between the new penems and amikacin was detected in 30% of the strains studied. Antagonism occurred with some Gram-positive bacteria.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3478328     DOI: 10.1093/jac/20.2.179

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  Pharmacokinetics of FCE 22891, a new oral penem.

Authors:  A Saathoff; H Lode; B Hampel; K M Deppermann; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  In vitro activities of new antimicrobial agents against multiresistant Staphylococcus aureus isolated from septicemic patients during a Belgian national survey from 1983 to 1985.

Authors:  P Van der Auwera; C Godard; C Denis; S De Maeyer; R Vanhoof
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

3.  Failure of routine susceptibility tests to detect imipenem resistance among strains of methicillin-resistant Staphylococcus aureus.

Authors:  J M Boyce; E Papa; R Dickenson; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

4.  In vitro activity of FCE 22101, imipenem, and ceftazidime against over 6,000 bacterial isolates and MIC quality control limits of FCE 22101.

Authors:  A L Barry; K E Aldridge; S D Allen; P C Fuchs; E H Gerlach; R N Jones; M A Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

5.  In vitro activity of CP-65,207, a new penem antimicrobial agent, in comparison with those of other agents.

Authors:  T Gootz; J Retsema; A Girard; E Hamanaka; M Anderson; S Sokolowski
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

6.  The effect of FCE 22891, a new oral penem, on faecal flora anaerobes and their fermentation end products in patients with chronic obstructive pulmonary disease.

Authors:  G J Meijer-Severs; E van Santen; S M Puister; W G Boersma
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.